Quarterly ResultMay 12, 2026, 07:12 AM
Sionna Q1 Net Loss $26.8M; SION-719 Phase 2a Enrollment Complete
AI Summary
Sionna Therapeutics reported a net loss of $26.8 million for the first quarter of 2026, an increase from $16.5 million in the prior year, primarily due to higher research and development and general and administrative expenses. The company announced the completion of enrollment in its PreciSION CF Phase 2a trial for SION-719, with topline data expected in Summer 2026. Sionna also maintained a strong cash position of $289.9 million, which is projected to fund operations into 2028.
Key Highlights
- Q1 2026 net loss was $26.8 million, compared to $16.5 million in Q1 2025.
- Research and development expenses increased to $19.0 million from $13.7 million YoY.
- General and administrative expenses rose to $10.6 million from $6.0 million YoY.
- Cash, cash equivalents, and marketable securities totaled $289.9 million as of March 31, 2026.
- Current cash position is expected to fund operations into 2028.
- Enrollment completed in the PreciSION CF Phase 2a trial for NBD1 stabilizer SION-719.
- Topline data for SION-719 and SION-451 trials are anticipated in Summer 2026.